Clinical research on lung cancer at the "Oberig" clinic

UPD December 25, 2024: Dear patients, we inform you that the recruitment of patients for this clinical study is COMPLETED.

Since July 2024, the Universal Clinic "Oberig" has begun recruiting patients for a clinical study, within the framework of which patients with stage III lung cancer will be treated.

Lung cancer is the most common oncological disease in the world and in Ukraine in particular. Unfortunately, this aggressive tumor does not manifest itself symptomatically in the initial stages in most cases. But it is detection in the early stages that can give a successful result in treatment.

"Every year, about 13 thousand new cases of lung cancer are recorded in Ukraine. Men are 5 times more likely to get sick than women. At the same time, lung cancer is one of the few nosologies, the incidence of which in Ukraine is decreasing by 3-4% every year," comments the chief physician of the National Cancer Institute Andriy Beznosenko.

However, the most common symptoms may indicate a pathological process:

• a cough that does not go away and gets worse;
• coughing up blood or red-brown sputum;
• chest pain that worsens with deep breathing, coughing, or laughing;
• wheezing;
• loss of weight and appetite;
• shortness of breath;
• a constant feeling of fatigue or weakness;
• infections, including bronchitis and pneumonia, that do not go away or recur.

If these symptoms appear, you should not panic, as they are characteristic of most lung diseases, but this is definitely a reason to see a doctor who will diagnose and prescribe appropriate treatment.

Clinical trials for patients with a history of cancer are often the best treatment option. As part of the trial of new drugs, the patient has the opportunity to receive free standard therapy according to international standards, even if not all of these drugs are registered in Ukraine, receive all diagnostics and medical support also free of charge as part of the study.

From July 2024, the Oberig Universal Clinic will begin recruiting for a clinical study for patients with stage III lung cancer. Chemoradiotherapy according to NCCN guidelines will be used for treatment for both study groups, the difference between the study groups will be in the immunotherapy options:

• Group I receives 17 courses of durvalumab after chemoradiotherapy. Durvalumab is an antibody that blocks programmed death ligand 1 (PD-L1), which promotes a normal immune response that attacks tumor cells.
• Group II receives the study drug in parallel with standard chemoradiotherapy and continues after the end of cCRT.

The study drug is a combination of pembrolizumab and vibostolimab (anti-TIGIT monoclonal antibody that binds to the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), blocking the interaction between TIGIT and its ligands CD112 and CD155, thereby activating T-lymphocytes that contribute to the destruction of tumor cells).

Extended selection criteria can be found under the code MK-7684A-006 on the website of the State Expert Center of the Ministry of Health of Ukraine: https://clinicaltrials.dec.gov.ua/Detail.aspx . But it is worth understanding that the patient does not have to have all the examinations before entering treatment, we can conduct the examination free of charge during the screening period at the Oberig clinic.

For detailed information, please contact the phone number: 063-652-31-38, Natalia Slobodyanyuk.